11 completed, 10 active not recruiting, 7 unknown, 6 recruiting. 21 Phase 2, 8 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Recruiting 6, Active not recruiting 5, Unknown 5, Completed 4, Terminated 1 |
| Phase 1 | 8 | Completed 6, Active not recruiting 2 |
| Phase 3 | 4 | Active not recruiting 3, Completed 1 |
Follow lazertinib: new trials by email Literature Review of lazertinib trials Research Report on lazertinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC Amivantamab, Lazertinib, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Janssen Research & Development, LLC | 68 | 2026-07-28 | 2026-11-03 |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Amivantamab, Lazertinib, Chemotherapy: Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Janssen Research & Development, LLC | 480 | 2024-12-16 | 2026-11-03 |
| Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment Lazertinib, Tepotinib - Non-Small Cell Lung Cancer Metastatic | Phase 2 | Recruiting | Sehhoon Park | 47 | 2024-06-11 | 2026-09-10 |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib Amivantamab IV, Amivantamab SC, Lazertinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 305 | 2024-02-16 | 2026-11-03 |
| A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker Lazertinib, Bevacizumab Injectable Product - Lazertinib | Phase 2 | Recruiting | National Cancer Center, Korea | 120 | 2023-09-05 | 2023-12-05 |
| Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Lazertinib+Pemetrexed+Carboplatin, Lazertinib - Non Small Cell Lung Cancer | Phase 2 | Unknown | Yonsei University | 129 | 2023-09-01 | 2023-09-01 |
| A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants Lazertinib - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 72 | 2023-05-30 | 2025-02-03 |
| Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations Amivantamab, Lazertinib, Pemetrexed 500 mg - Metastatic Non-small Cell Lung Cancers | Phase 2 | Completed | Latin American Cooperative Oncology Group | 54 | 2023-05-24 | 2026-08-28 |
| Premedication to Reduce Amivantamab Associated Infusion Related Reactions Dexamethasone, Montelukast, Methotrexate - Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 68 | 2023-05-18 | 2026-11-03 |
| Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib Lazertinib/Pemetrexed/Carboplatin - Non-small Cell Lung Cancer | Phase 2 | Completed | Yonsei University | 65 | 2023-04-07 | 2026-10-07 |
| Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI Amivantamab, Lazertinib, Zirabev - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 60 | 2023-03-27 | 2026-11-12 |
| Impact of Lazertinib Dose Modification on Effectiveness and Safety Lazertinib - Non-small Cell Lung Cancer | Unknown | Pusan National University Hospital | 200 | 2023-02-01 | 2023-02-08 | |
| Lazertinib 160mg in EGFR T790M NSCLC Lazertinib - Lung Cancer Stage IV, EGFR T790M | Phase 2 | Unknown | Samsung Medical Center | 117 | 2023-02-01 | 2023-01-27 |
| To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation Vabametkib, Lazertinib - Advanced Solid Tumors | Phase 2 | Recruiting | Abion Inc | 178 | 2023-01-17 | 2025-05-22 |
| Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients Lazertinib group - NSCLC | Phase 2 | Active not recruiting | Sehhoon Park | 150 | 2023-01-04 | 2026-07-28 |
| A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants Lazertinib - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 64 | 2023-01-03 | 2023-06-02 |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer Amivantamab, Lazertinib, Carboplatin - Carcinoma, Non-small-Cell Lung | Phase 2 | Recruiting | Janssen Research & Development, LLC | 520 | 2022-11-11 | 2026-11-03 |
| Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases Lazertinib, Pemetrexed, Carboplatin - Non-small Cell Lung Cancer | Phase 2 | Terminated | Jin Hyoung Kang | 14 | 2022-08-12 | 2026-10-08 |
| A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous - Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 418 | 2022-08-05 | 2026-11-03 |
| Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer Lazertinib - Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M | Unknown | Samsung Medical Center | 900 | 2022-07-31 | 2022-05-19 |
Showing 20 of 36. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (23) · Lung Neoplasms (2) · Adenocarcinoma of Lung (1)
Janssen Research & Development, LLC (16) · Yonsei University (5) · Yuhan Corporation (3) · Samsung Medical Center (2) · Sehhoon Park (2) · Abion Inc (1) · ETOP IBCSG Partners Foundation (1) · Jin Hyoung Kang (1) · Latin American Cooperative Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Center, Korea (1) · Pusan National University Hospital (1) · Sung Yong Lee (1)
South Korea (24) · United States (16) · Spain (12) · France (10) · Taiwan (10) · China (8) · Germany (8) · United Kingdom (8) · Italy (7) · Brazil (6) · Japan (6) · Malaysia (6) · Canada (5) · Israel (5) · Turkey (Türkiye) (5)
Hye Ryun Kim (2) · Helena Yu, MD (1) · Jin Hyoung Kang (1) · Jin Seok Ahn, MD, PhD (1) · Min Ki Lee, MD, PhD (1) · MinHee Hong (1) · Ross Soo, MD FRACP (1) · Sehhoon Park (1) · Sehhoon Park, MD (1) · Sun Min Lim (1) · Sung Yong Lee, MD, PhD (1)
PMID 34339261, PMID 34339292, PMID 34911336, PMID 35962934, PMID 35963523, PMID 36002368, PMID 36268845, PMID 36652175, PMID 37022784, PMID 37379502, PMID 37589131, PMID 37710001, PMID 37865896, PMID 38476120, PMID 38857463, PMID 38924756, PMID 39033692, PMID 39755170, PMID 39864547, PMID 39918363, PMID 40350080, PMID 40383434, PMID 40617394, PMID 40923797, PMID 40923969, PMID 41139066, PMID 41259729, PMID 41927036, PMID 42635093, PMID 42833236, PMID 42870814
2023 (6), 2018 (1), 2019 (1), 2025 (1)